Biggest News Aggregation in the World
📰 Nasdaq Knte News

Nasdaq Knte News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Knte. Real-time updates on events, politics, business and more.

Acuitas Investments LLC Invests $687,000 in Kinnate Biopharma Inc. (NASDAQ:KNTE)

Acuitas Investments LLC purchased a new position in Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 289,766 shares of the company’s stock, valued at approximately $687,000. Acuitas Investments LLC owned approximately 0.62% of Kinnate Biopharma […]
United States William Blair Kinnate Biopharma Stifel Nicolaus Citigroup Inc Capital Management

Pale Fire Capital SE Raises Position in Kinnate Biopharma Inc. (NASDAQ:KNTE)

Pale Fire Capital SE raised its stake in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) by 196.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,174 shares of the company’s stock after acquiring an additional 46,492 shares during the quarter. Pale […]
United States Kinnate Biopharma William Blair Metlife Investment Management Kinnate Biopharma Inc Jpmorgan Chase Co

Kinnate Biopharma Inc. (NASDAQ:KNTE) Receives Consensus Rating of "Hold" from Brokerages

Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Free Report) has earned a consensus rating of “Hold” from the five brokerages that are covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among […]
United States Kinnate Biopharma Tower Research Capital Kinnate Biopharma Inc Principal Financial Group Inc Kinnate Biopharma Company Profile
Source: wkrb13.com

Harvard Management Co. Inc. Has $1.40 Million Holdings in Kinnate Biopharma Inc. (NASDAQ:KNTE)

Harvard Management Co. Inc. trimmed its stake in Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) by 7.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 462,418 shares of the company’s stock after selling 35,583 shares during the period. Kinnate Biopharma comprises approximately […]
United States Kinnate Biopharma Piper Sandler Principal Financial Group Inc Kinnate Biopharma Company Profile Kinnate Biopharma Inc
Source: wkrb13.com

FY2023 Earnings Estimate for Kinnate Biopharma Inc. (NASDAQ:KNTE) Issued By Wedbush

Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) – Equities researchers at Wedbush raised their FY2023 earnings per share estimates for Kinnate Biopharma in a report released on Tuesday, September 19th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($2.23) for the year, up from their prior estimate of […]
United States Piper Sandler Kinnate Biopharma Principal Financial Group Inc Kinnate Biopharma Inc Tower Research Capital
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Q3 2023 EPS Estimates for Kinnate Biopharma Inc. Increased by HC Wainwright (NASDAQ:KNTE)

Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) – Stock analysts at HC Wainwright increased their Q3 2023 earnings per share estimates for shares of Kinnate Biopharma in a report released on Tuesday, August 15th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.73) per share for the quarter, up from their […]
United States Kinnate Biopharma Principal Financial Group Inc Goldman Sachs Group Tower Research Capital Kinnate Biopharma Inc

Kinnate Biopharma (NASDAQ:KNTE) Stock Rating Reaffirmed by 500.com

Kinnate Biopharma (NASDAQ:KNTE – Get Rating)‘s stock had its “maintains” rating reaffirmed by research analysts at 500.com in a research report issued on Thursday, Benzinga reports. Other analysts also recently issued reports about the company. The Goldman Sachs Group decreased their price target on Kinnate Biopharma from $29.00 to $26.00 and set a “buy” rating […]
United States Jamesb Tananbaum Kinnate Biopharma Stifel Nicolaus Foresite Capital Management Securities Exchange Commission

Kinnate Biopharma (NASDAQ:KNTE) Receives Maintains Rating from 500.com

500.com restated their maintains rating on shares of Kinnate Biopharma (NASDAQ:KNTE – Get Rating) in a report released on Thursday, Benzinga reports. A number of other brokerages have also commented on KNTE. Stifel Nicolaus dropped their price target on Kinnate Biopharma from $8.00 to $5.00 in a research note on Tuesday, April 18th. HC Wainwright […]
United States Kinnate Biopharma Stifel Nicolaus Carll Gordon Securities Exchange Commission Blackrock Inc
Source: wkrb13.com

Kinnate Biopharma (NASDAQ:KNTE) Price Target Cut to $24.00 by Analysts at HC Wainwright

Kinnate Biopharma (NASDAQ:KNTE – Get Rating) had its price objective trimmed by HC Wainwright from $25.00 to $24.00 in a research note released on Thursday morning, The Fly reports. A number of other research analysts have also recently issued reports on the company. Wedbush reduced their price objective on Kinnate Biopharma from $25.00 to $14.00 […]
United States Kinnate Biopharma Stifel Nicolaus Carll Gordon Simplex Trading Securities Exchange Commission
Source: wkrb13.com

Short Interest in Kinnate Biopharma Inc. (NASDAQ:KNTE) Decreases By 16.6%

Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Rating) was the target of a significant decline in short interest in the month of April. As of April 30th, there was short interest totalling 1,510,000 shares, a decline of 16.6% from the April 15th total of 1,810,000 shares. Approximately 6.9% of the shares of the company are sold […]
United States Jamesb Tananbaum Stifel Nicolaus Kinnate Biopharma Goldman Sachs Group Kinnate Biopharma Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science